Rani Therapeutics Holdings Stock Buy Hold or Sell Recommendation
| RANI Stock | USD 1.99 0.04 2.05% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Rani Therapeutics Holdings is 'Cautious Hold'. The recommendation algorithm takes into account all of Rani Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Rani Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Rani and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Rani |
Execute Rani Therapeutics Buy or Sell Advice
The Rani recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Rani Therapeutics Holdings. Macroaxis does not own or have any residual interests in Rani Therapeutics Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Rani Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Rani Therapeutics Trading Alerts and Improvement Suggestions
| Rani Therapeutics generated a negative expected return over the last 90 days | |
| Rani Therapeutics has high historical volatility and very poor performance | |
| Rani Therapeutics may become a speculative penny stock | |
| Rani Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (33.97 M) with profit before overhead, payroll, taxes, and interest of 2.72 M. | |
| Rani Therapeutics Holdings currently holds about 98.17 M in cash with (51.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Rani Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: RANI Third Quarter Update |
Rani Therapeutics Returns Distribution Density
The distribution of Rani Therapeutics' historical returns is an attempt to chart the uncertainty of Rani Therapeutics' future price movements. The chart of the probability distribution of Rani Therapeutics daily returns describes the distribution of returns around its average expected value. We use Rani Therapeutics Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Rani Therapeutics returns is essential to provide solid investment advice for Rani Therapeutics.
| Mean Return | -0.34 | Value At Risk | -9.34 | Potential Upside | 8.71 | Standard Deviation | 9.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Rani Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Rani Stock Institutional Investors
| Shares | Lasry Marc | 2024-06-30 | 62.9 K | Motco | 2024-09-30 | 48.1 K | State Street Corp | 2024-06-30 | 42 K | Renaissance Technologies Corp | 2024-09-30 | 33.2 K | Brown Advisory Holdings Inc | 2024-09-30 | 32.9 K | Citadel Advisors Llc | 2024-09-30 | 26.9 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 21.2 K | Lafayette Investments, Inc. | 2024-06-30 | 19.9 K | Tower Research Capital Llc | 2024-06-30 | 14.4 K | Armistice Capital, Llc | 2024-09-30 | 2.6 M | Vanguard Group Inc | 2024-09-30 | 709.8 K |
Rani Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Rani Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Rani Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Rani stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.7 | |
β | Beta against Dow Jones | 3.01 | |
σ | Overall volatility | 9.79 | |
Ir | Information ratio | -0.05 |
Rani Therapeutics Volatility Alert
Rani Therapeutics Holdings is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Rani Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Rani Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Rani Therapeutics Fundamentals Vs Peers
Comparing Rani Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rani Therapeutics' direct or indirect competition across all of the common fundamentals between Rani Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rani Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Rani Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rani Therapeutics to competition |
| Fundamentals | Rani Therapeutics | Peer Average |
| Return On Equity | -2.25 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Current Valuation | 69.62 M | 16.62 B |
| Shares Outstanding | 33.31 M | 571.82 M |
| Shares Owned By Insiders | 30.61 % | 10.09 % |
| Shares Owned By Institutions | 19.58 % | 39.21 % |
| Number Of Shares Shorted | 1.6 M | 4.71 M |
| Price To Book | 21.25 X | 9.51 X |
| Price To Sales | 313.17 X | 11.42 X |
| Gross Profit | 2.72 M | 27.38 B |
| EBITDA | (65.28 M) | 3.9 B |
| Net Income | (33.97 M) | 570.98 M |
| Cash And Equivalents | 98.17 M | 2.7 B |
| Cash Per Share | 3.97 X | 5.01 X |
| Total Debt | 30.1 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 14.02 X | 2.16 X |
| Book Value Per Share | 0.49 X | 1.93 K |
| Cash Flow From Operations | (51.24 M) | 971.22 M |
| Short Ratio | 0.36 X | 4.00 X |
| Earnings Per Share | (1.05) X | 3.12 X |
| Price To Earnings To Growth | 0.68 X | 4.89 X |
| Target Price | 11.5 | |
| Number Of Employees | 140 | 18.84 K |
| Beta | 0.11 | -0.15 |
| Market Capitalization | 116.52 M | 19.03 B |
| Total Asset | 57.92 M | 29.47 B |
| Retained Earnings | (72.89 M) | 9.33 B |
| Working Capital | 42.86 M | 1.48 B |
| Net Asset | 57.92 M |
Note: Acquisition by Ausiello Dennis A of 50000 shares of Rani Therapeutics at 5.0 subject to Rule 16b-3 [view details]
Rani Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Rani . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Rani Therapeutics Buy or Sell Advice
When is the right time to buy or sell Rani Therapeutics Holdings? Buying financial instruments such as Rani Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Rani Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tips ETFs Thematic Idea Now
Tips ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Rani Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.57) | Return On Equity (2.25) |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.